EG436523 Inhibitors
EG436523 inhibitors are a class of small-molecule compounds known for their role in modulating specific enzymatic activities at a molecular level. These inhibitors are structurally diverse, allowing them to interact with a wide array of target proteins within cellular pathways. The molecular architecture of EG436523 inhibitors often includes hydrophobic regions and functional groups capable of forming hydrogen bonds, electrostatic interactions, or van der Waals forces with their target proteins, leading to high specificity and binding affinity. This ability to specifically bind and inhibit target enzymes makes EG436523 inhibitors powerful tools for studying biochemical and cellular processes in various research settings. Their design often leverages structure-activity relationship (SAR) analysis to optimize binding efficiency and selectivity toward the desired target, which enhances their capacity to alter molecular functions in controlled settings.
These inhibitors often exert their action by binding to the active site or an allosteric site of the target protein, thereby influencing protein conformation, stability, and activity. This binding can either prevent the substrate from accessing the active site or induce a conformational change that decreases the enzyme's catalytic activity. The specificity of EG436523 inhibitors allows researchers to dissect complex cellular pathways and understand protein-protein interactions and signal transduction mechanisms. Because these inhibitors can be synthesized and modified to fine-tune their binding characteristics, they are commonly utilized in biochemical assays, molecular biology studies, and various forms of cellular experimentation. Their ability to interfere with specific molecular pathways provides valuable insights into cellular processes such as signal transduction, protein modification, and gene expression regulation, making them key molecular probes in fundamental biochemical research.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gabexate mesylate | 56974-61-9 | sc-215066 | 5 mg | $100.00 | ||
Serine protease inhibitor targeting trypsin-like enzymes. Gabexate mesylate directly inhibits Prss1l by binding to its active site, preventing substrate cleavage. This inhibition hinders the serine-type endopeptidase activity predicted for Prss1l and disrupts its role in proteolysis within the collagen-containing extracellular matrix. | ||||||
Nafamostat mesylate | 82956-11-4 | sc-201307 sc-201307A | 10 mg 50 mg | $82.00 $306.00 | 4 | |
Broad-spectrum serine protease inhibitor affecting trypsin-like enzymes. Nafamostat mesylate directly inhibits Prss1l, impeding its predicted serine-type endopeptidase activity and disrupting its involvement in proteolysis within the extracellular matrix. This inhibition is achieved by blocking the active site of Prss1l and preventing substrate cleavage. | ||||||
Camostat mesylate | 59721-29-8 | sc-203867 sc-203867A sc-203867B sc-203867C sc-203867D sc-203867E | 10 mg 50 mg 500 mg 1 g 10 g 100 g | $43.00 $183.00 $312.00 $624.00 $2081.00 $4474.00 | 5 | |
TMPRSS2 inhibitor with serine protease inhibitory activity. Camostat mesylate directly targets Prss1l, inhibiting its serine-type endopeptidase activity and impeding its role in proteolysis within the collagen-containing extracellular matrix. The inhibition is achieved by blocking the active site of Prss1l, preventing substrate cleavage. | ||||||
Aprotinin | 9087-70-1 | sc-3595 sc-3595A sc-3595B | 10 mg 100 mg 1 g | $112.00 $408.00 $3000.00 | 51 | |
Kunitz-type serine protease inhibitor. Aprotinin directly inhibits Prss1l, disrupting its predicted serine-type endopeptidase activity involved in proteolysis within the collagen-containing extracellular matrix. This inhibition occurs by binding to the active site of Prss1l and preventing substrate cleavage. | ||||||
Benzamidine | 618-39-3 | sc-233933 | 10 g | $292.00 | 1 | |
Broad-spectrum serine protease inhibitor. Benzamidine directly inhibits Prss1l by binding to its active site, hindering the serine-type endopeptidase activity predicted for Prss1l. This inhibition disrupts the proteolytic role of Prss1l within the collagen-containing extracellular matrix by preventing substrate cleavage. | ||||||
AEBSF hydrochloride | 30827-99-7 | sc-202041 sc-202041A sc-202041B sc-202041C sc-202041D sc-202041E | 50 mg 100 mg 5 g 10 g 25 g 100 g | $65.00 $122.00 $428.00 $851.00 $1873.00 $4994.00 | 33 | |
Serine protease inhibitor. AEBSF directly targets Prss1l, inhibiting its predicted serine-type endopeptidase activity involved in proteolysis within the collagen-containing extracellular matrix. This inhibition occurs by binding to the active site of Prss1l and preventing substrate cleavage. | ||||||
TPCK | 402-71-1 | sc-201297 | 1 g | $182.00 | 2 | |
Broad-spectrum serine protease inhibitor. TPCK directly inhibits Prss1l, impeding its predicted serine-type endopeptidase activity involved in proteolysis within the collagen-containing extracellular matrix. The inhibition is achieved by binding to the active site of Prss1l and preventing substrate cleavage. | ||||||
L-Lysine | 56-87-1 | sc-207804 sc-207804A sc-207804B | 25 g 100 g 1 kg | $95.00 $263.00 $529.00 | ||
Broad-spectrum serine protease inhibitor. TLCK (N-α-p-Tosyl-L-lysine chloromethyl ketone hydrochloride) directly targets Prss1l, inhibiting its serine-type endopeptidase activity involved in proteolysis within the collagen-containing extracellular matrix. This inhibition occurs by binding to the active site of Prss1l and preventing substrate cleavage. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
Cysteine protease inhibitor with inhibitory activity against serine proteases. E-64 directly inhibits Prss1l, hindering its serine-type endopeptidase activity involved in proteolysis within the collagen-containing extracellular matrix. This inhibition is achieved by blocking the active site of Prss1l and preventing substrate cleavage. | ||||||